Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-11-01 |
{
"resourceType" : "Evidence",
"id" : "236984",
"meta" : {
"versionId" : "61",
"lastUpdated" : "2024-10-03T13:11:20.368Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Evidence 236984</b></p><a name=\"236984\"> </a><a name=\"hc236984\"> </a><a name=\"236984-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 61; Last updated: 2024-10-03 13:11:20+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-comparative-evidence.html\">ComparativeEvidence</a></p></div><p><b>url</b>: <a href=\"Evidence-236984.html\">Evidence MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes</a></p><p><b>identifier</b>: FEvIR Object Identifier/236984, outcomeId/109587, picoId/85798, sectionId/73215, <a href=\"http://terminology.hl7.org/6.0.2/NamingSystem-uri.html\" title=\"As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt \r\n\r\nThis oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: \r\n\r\nNote that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.\r\n\r\nThis OID may also be used in CD.codeSystem.\">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.22.58</p><p><b>version</b>: 2.0.0-ballot</p><p><b>name</b>: Health_related_quality_of_lifefrom_MAGICapp_109587</p><p><b>title</b>: MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes</p><p><b>status</b>: Active</p><p><b>date</b>: 2024-11-01 10:20:00+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href=\"http://www.hl7.org/Special/committees/dss\">http://www.hl7.org/Special/committees/dss</a></p><p><b>author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ComparativeEvidence}\">ComparativeEvidence</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><h3>RelatedArtifacts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>ResourceReference</b></td></tr><tr><td style=\"display: none\">*</td><td>Part Of</td><td>MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</td></tr></table><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><p><b>assertion</b>: </p><div><p>There may be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on health-related quality of life.</p>\n</div><blockquote><p><b>variableDefinition</b></p><p><b>org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code</b>: population</p><p><b>description</b>: </p><div><p>Adults with type 2 diabetes</p>\n</div><p><b>note</b>: population</p><p><b>observed</b>: <a href=\"Group-236947.html\">Adults with type 2 diabetes and CVD and CKD</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code</b>: exposure</p><p><b>org/fhir/uv/ebm/StructureDefinition/variable-definition-comparator-category</b>: GLP-1 RA</p><p><b>description</b>: </p><div><p>GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</p>\n</div><p><b>note</b>: exposure</p><p><b>observed</b>: <a href=\"EvidenceVariable-236950.html\">GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code</b>: outcome</p><p><b>description</b>: </p><div><p>Health-related quality of life</p>\n</div><p><b>note</b>: outcome</p><p><b>observed</b>: <a href=\"EvidenceVariable-236983.html\">Health-related quality of life</a></p></blockquote><p><b>synthesisType</b>: <span title=\"Codes:\">SYSTEMATIC_REVIEW</span></p><p><b>studyDesign</b>: <span title=\"Codes:\">NOTSET</span></p><blockquote><p><b>statistic</b></p><p><b>description</b>: </p><div><p>SMD 0.01 (CI95 -0.19 to 0.2 )</p>\n</div><p><b>statisticType</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/statistic-type 0000100}\">Standardized Mean Difference</span></p><p><b>quantity</b>: 0.01</p><h3>AttributeEstimates</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Range</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">CI95</span></td><td>-0.19-0.2</td></tr></table></blockquote><blockquote><p><b>certainty</b></p><p><b>description</b>: </p><div><p>Due to very serious imprecision</p>\n</div><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-type Overall}\">Overall certainty</span></p><p><b>rating</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/27834 RJCS-2005}\">Low certainty</span></p><h3>Subcomponents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Rating</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Risk of Bias</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Inconsistency</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Indirectness</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Imprecision</span></td><td><span title=\"Codes:\">VERY_SERIOUS</span></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Publication Bias</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr></table></blockquote></div>"
},
"url" : "https://fevir.net/resources/Evidence/236984",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net",
"value" : "236984",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"type" : {
"text" : "outcomeId"
},
"system" : "https://app.magicapp.org/#/guidelines",
"value" : "109587"
},
{
"type" : {
"text" : "picoId"
},
"system" : "https://app.magicapp.org/#/guidelines",
"value" : "85798"
},
{
"type" : {
"text" : "sectionId"
},
"system" : "https://app.magicapp.org/#/guidelines",
"value" : "73215"
},
{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113883.4.642.40.44.22.58"
}
],
"version" : "2.0.0-ballot",
"name" : "Health_related_quality_of_lifefrom_MAGICapp_109587",
"title" : "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"status" : "active",
"date" : "2024-11-01T10:20:00+00:00",
"publisher" : "HL7 International / Clinical Decision Support",
"contact" : [
{
"name" : "HL7 International / Clinical Decision Support",
"telecom" : [
{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/dss"
}
]
}
],
"author" : [
{
"name" : "Computable Publishing®: MAGIC-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ComparativeEvidence",
"display" : "ComparativeEvidence"
}
]
}
}
],
"copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"relatedArtifact" : [
{
"type" : "part-of",
"resourceReference" : {
"type" : "Composition",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-conversion-report",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
}
}
],
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"assertion" : "There may be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on health-related quality of life.",
"variableDefinition" : [
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code",
"valueCode" : "population"
}
],
"description" : "Adults with type 2 diabetes",
"note" : [
{
"text" : "population"
}
],
"observed" : {
🔗 "reference" : "Group/236947",
"type" : "Group",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-population-group-85394-85798",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Adults with type 2 diabetes and CVD and CKD"
}
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code",
"valueCode" : "exposure"
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-comparator-category",
"valueString" : "GLP-1 RA"
}
],
"description" : "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA",
"note" : [
{
"text" : "exposure"
}
],
"observed" : {
🔗 "reference" : "EvidenceVariable/236950",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-group-assignment-85394-85798",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA"
}
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code",
"valueCode" : "outcome"
}
],
"description" : "Health-related quality of life",
"note" : [
{
"text" : "outcome"
}
],
"observed" : {
🔗 "reference" : "EvidenceVariable/236983",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-109587",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Health-related quality of life"
}
}
],
"synthesisType" : {
"text" : "SYSTEMATIC_REVIEW"
},
"studyDesign" : [
{
"text" : "NOTSET"
}
],
"statistic" : [
{
"description" : "SMD 0.01 (CI95 -0.19 to 0.2 )",
"statisticType" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/statistic-type",
"version" : "5.0.0-cibuild",
"code" : "0000100",
"display" : "Standardized Mean Difference"
}
]
},
"quantity" : {
"value" : 0.01
},
"attributeEstimate" : [
{
"type" : {
"text" : "CI95"
},
"range" : {
"low" : {
"value" : -0.19
},
"high" : {
"value" : 0.2
}
}
}
]
}
],
"certainty" : [
{
"description" : "Due to very serious imprecision",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-type",
"code" : "Overall",
"display" : "Overall certainty"
}
]
},
"rating" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-2005",
"display" : "Low certainty"
}
]
},
"subcomponent" : [
{
"type" : {
"text" : "Risk of Bias"
},
"rating" : {
"text" : "NOTSET"
}
},
{
"type" : {
"text" : "Inconsistency"
},
"rating" : {
"text" : "NOTSET"
}
},
{
"type" : {
"text" : "Indirectness"
},
"rating" : {
"text" : "NOTSET"
}
},
{
"type" : {
"text" : "Imprecision"
},
"rating" : {
"text" : "VERY_SERIOUS"
}
},
{
"type" : {
"text" : "Publication Bias"
},
"rating" : {
"text" : "NOTSET"
}
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-01
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change